Cargando…

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery

BACKGROUND: To compare the safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% (LE ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery. METHODS: Two randomized, multicenter, double-masked, parallel-group,...

Descripción completa

Detalles Bibliográficos
Autores principales: Comstock, Timothy L, Paterno, Michael R, Singh, Angele, Erb, Tara, Davis, Elizabeth
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045067/
https://www.ncbi.nlm.nih.gov/pubmed/21383946
http://dx.doi.org/10.2147/OPTH.S16832
_version_ 1782198794253762560
author Comstock, Timothy L
Paterno, Michael R
Singh, Angele
Erb, Tara
Davis, Elizabeth
author_facet Comstock, Timothy L
Paterno, Michael R
Singh, Angele
Erb, Tara
Davis, Elizabeth
author_sort Comstock, Timothy L
collection PubMed
description BACKGROUND: To compare the safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% (LE ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery. METHODS: Two randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies were conducted. Patients aged ≥18 years with a combined postoperative anterior chamber cells and flare (ACI) ≥ Grade 3 following uncomplicated cataract surgery participated in seven study visits. Patients self-administered either topical LE ointment or vehicle four times daily for 14 days. Efficacy outcomes included the proportion of patients with complete resolution of ACI and the proportion of patients with no (Grade 0) pain at postoperative day 8. Safety outcomes included the incidence of adverse events, ocular symptoms, changes in intraocular pressure and visual acuity, and biomicroscopy and funduscopy findings. RESULTS: Data from the two studies were combined. The integrated intent-to-treat population consisted of 805 patients (mean [standard deviation] age 69.0 [9.2] years; 58.0% female and 89.7% white). Significantly more LE ointment-treated patients than vehicle-treated patients had complete resolution of ACI (27.7% versus 12.5%) and no pain (75.5% versus 43.1%) at day 8 (P < 0.0001 for both). Fewer LE ointment-treated patients required rescue medication (27.7% versus 63.8%), and fewer had an ocular adverse event (47.2% versus 78.0%, P < 0.0001) while on study treatment. The most common ocular adverse events with LE ointment were anterior chamber inflammation, photophobia, corneal edema, conjunctival hyperemia, eye pain, and iritis. Mean intraocular pressure decreased in both treatment groups. Four patients had increased intraocular pressure ≥10 mmHg (three LE ointment and one vehicle) prior to rescue medication. Visual acuity and dilated funduscopy results were similar between the treatment groups, with the exception of visual acuity at visits 5 and 6, which favored LE ointment. CONCLUSION: LE ointment was efficacious and well tolerated in the treatment of ocular inflammation and pain following cataract surgery.
format Text
id pubmed-3045067
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30450672011-03-07 Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery Comstock, Timothy L Paterno, Michael R Singh, Angele Erb, Tara Davis, Elizabeth Clin Ophthalmol Original Research BACKGROUND: To compare the safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% (LE ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery. METHODS: Two randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies were conducted. Patients aged ≥18 years with a combined postoperative anterior chamber cells and flare (ACI) ≥ Grade 3 following uncomplicated cataract surgery participated in seven study visits. Patients self-administered either topical LE ointment or vehicle four times daily for 14 days. Efficacy outcomes included the proportion of patients with complete resolution of ACI and the proportion of patients with no (Grade 0) pain at postoperative day 8. Safety outcomes included the incidence of adverse events, ocular symptoms, changes in intraocular pressure and visual acuity, and biomicroscopy and funduscopy findings. RESULTS: Data from the two studies were combined. The integrated intent-to-treat population consisted of 805 patients (mean [standard deviation] age 69.0 [9.2] years; 58.0% female and 89.7% white). Significantly more LE ointment-treated patients than vehicle-treated patients had complete resolution of ACI (27.7% versus 12.5%) and no pain (75.5% versus 43.1%) at day 8 (P < 0.0001 for both). Fewer LE ointment-treated patients required rescue medication (27.7% versus 63.8%), and fewer had an ocular adverse event (47.2% versus 78.0%, P < 0.0001) while on study treatment. The most common ocular adverse events with LE ointment were anterior chamber inflammation, photophobia, corneal edema, conjunctival hyperemia, eye pain, and iritis. Mean intraocular pressure decreased in both treatment groups. Four patients had increased intraocular pressure ≥10 mmHg (three LE ointment and one vehicle) prior to rescue medication. Visual acuity and dilated funduscopy results were similar between the treatment groups, with the exception of visual acuity at visits 5 and 6, which favored LE ointment. CONCLUSION: LE ointment was efficacious and well tolerated in the treatment of ocular inflammation and pain following cataract surgery. Dove Medical Press 2011 2011-02-10 /pmc/articles/PMC3045067/ /pubmed/21383946 http://dx.doi.org/10.2147/OPTH.S16832 Text en © 2011 Comstock et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Comstock, Timothy L
Paterno, Michael R
Singh, Angele
Erb, Tara
Davis, Elizabeth
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
title Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
title_full Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
title_fullStr Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
title_full_unstemmed Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
title_short Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
title_sort safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045067/
https://www.ncbi.nlm.nih.gov/pubmed/21383946
http://dx.doi.org/10.2147/OPTH.S16832
work_keys_str_mv AT comstocktimothyl safetyandefficacyofloteprednoletabonateophthalmicointment05forthetreatmentofinflammationandpainfollowingcataractsurgery
AT paternomichaelr safetyandefficacyofloteprednoletabonateophthalmicointment05forthetreatmentofinflammationandpainfollowingcataractsurgery
AT singhangele safetyandefficacyofloteprednoletabonateophthalmicointment05forthetreatmentofinflammationandpainfollowingcataractsurgery
AT erbtara safetyandefficacyofloteprednoletabonateophthalmicointment05forthetreatmentofinflammationandpainfollowingcataractsurgery
AT daviselizabeth safetyandefficacyofloteprednoletabonateophthalmicointment05forthetreatmentofinflammationandpainfollowingcataractsurgery